Literature DB >> 8695828

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

E Estey, S Kornblau, S Pierce, H Kantarjian, M Beran, M Keating.   

Abstract

Entities:  

Mesh:

Year:  1996        PMID: 8695828

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  27 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

Authors:  Geoffrey L Uy; Michael P Rettig; Ibraheem H Motabi; Kyle McFarland; Kathryn M Trinkaus; Lindsay M Hladnik; Shashikant Kulkarni; Camille N Abboud; Amanda F Cashen; Keith E Stockerl-Goldstein; Ravi Vij; Peter Westervelt; John F DiPersio
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

3.  Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Authors:  Amer M Zeidan; Rebecca M Ricklis; Hetty E Carraway; Hyun D Yun; Jacqueline M Greer; B Douglas Smith; Mark J Levis; Michael A McDevitt; Keith W Pratz; Margaret M Showel; Douglas E Gladstone; Steven D Gore; Judith E Karp
Journal:  Br J Haematol       Date:  2012-05-18       Impact factor: 6.998

4.  Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.

Authors:  Roland B Walter; Megan Othus; Bob Löwenberg; Gert J Ossenkoppele; Stephen H Petersdorf; Thomas Pabst; Marie-Christiane Vekemans; Frederick R Appelbaum; Harry P Erba; Elihu H Estey
Journal:  Haematologica       Date:  2015-07-09       Impact factor: 9.941

5.  Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Guillermo Garcia-Manero; Sherry Pierce; Marylou Cardenas-Turanzas; Jorge Cortes; Farhad Ravandi
Journal:  Am J Hematol       Date:  2014-10-18       Impact factor: 10.047

6.  The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation.

Authors:  M Byrne; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

7.  Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Authors:  Fabiana Perna; Samuel H Berman; Rajesh K Soni; Jorge Mansilla-Soto; Justin Eyquem; Mohamad Hamieh; Ronald C Hendrickson; Cameron W Brennan; Michel Sadelain
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

Review 8.  Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.

Authors:  B Gyurkocza; H M Lazarus; S Giralt
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

9.  A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

Authors:  Daniel J DeAngelo; Andrew M Brunner; Lillian Werner; David Avigan; Amir T Fathi; Adam S Sperling; Abigail Washington; Dina Stroopinsky; Jacalyn Rosenblatt; Malgorzata McMasters; Katarina Luptakova; Martha Wadleigh; David P Steensma; Gabriela S Hobbs; Eyal C Attar; Philip C Amrein; Benjamin L Ebert; Richard M Stone; Karen K Ballen
Journal:  Am J Hematol       Date:  2017-11-21       Impact factor: 10.047

10.  SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.

Authors:  Anjali S Advani; Shannon McDonough; Edward Copelan; Cheryl Willman; Deborah A Mulford; Alan F List; Mikkael A Sekeres; Megan Othus; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2014-07-18       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.